promethazine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	2286	60-87-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: promethazine diphergan proazamine prometazin protazine promethazine hydrochloride promethazine HCl	A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals. Molecular weight: 284.42 Formula: C17H20N2S CLOGP: 4.60 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 6.48 ALOGS: -4.07 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

promethazine
diphergan
proazamine
prometazin
protazine
promethazine hydrochloride
promethazine HCl

A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.

Molecular weight: 284.42
Formula: C17H20N2S
CLOGP: 4.60
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 6.48
ALOGS: -4.07
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
25	mg	O
25	mg	P
25	mg	R

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	5.03 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	25 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	14 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	14 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.09 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	14 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
March 29, 1951	FDA	DELCOR ASSET CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional self-injury	6218.26	10.17	2042	75748	23242	53248034
Intentional overdose	5068.65	10.17	2294	75496	64911	53206365
Akathisia	499.88	10.17	246	77544	8325	53262951
Tachycardia	382.13	10.17	616	77174	107596	53163680
Depressed level of consciousness	369.99	10.17	426	77364	54002	53217274
Mydriasis	271.45	10.17	182	77608	11144	53260132
Drug ineffective	268.50	10.17	491	77299	816754	52454522
Cholecystitis chronic	264.11	10.17	174	77616	10344	53260932
Rheumatoid arthritis	238.11	10.17	81	77709	314450	52956826
Toxicity to various agents	187.92	10.17	724	77066	218874	53052402
Anxiety	171.10	10.17	652	77138	196052	53075224
Contraindicated product administered	161.19	10.17	9	77781	135620	53135656
Drug abuse	146.01	10.17	306	77484	65220	53206056
Synovitis	128.68	10.17	7	77783	107886	53163390
Nausea	128.07	10.17	1670	76120	754421	52516855
Suicide attempt	123.07	10.17	266	77524	57902	53213374
Hallucination	120.60	10.17	252	77538	53586	53217690
Treatment failure	120.46	10.17	21	77769	128382	53142894
Joint swelling	113.47	10.17	105	77685	234533	53036743
Drug intolerance	112.99	10.17	81	77709	205412	53065864
Off label use	110.13	10.17	339	77451	471873	52799403
Glossodynia	109.53	10.17	10	77780	100281	53170995
Vomiting	109.13	10.17	1155	76635	495984	52775292
Hand deformity	106.09	10.17	4	77786	84845	53186431
Poisoning	103.56	10.17	114	77676	13736	53257540
Completed suicide	103.14	10.17	437	77353	137764	53133512
Somnolence	99.68	10.17	496	77294	167238	53104038
Injury	92.12	10.17	219	77571	50752	53220524
Biliary dyskinesia	85.15	10.17	52	77738	2705	53268571
Gallbladder disorder	84.84	10.17	118	77672	18047	53253229
Agitation	83.26	10.17	230	77560	58396	53212880
Sinus tachycardia	80.05	10.17	132	77658	23440	53247836
Arthropathy	78.71	10.17	55	77735	141398	53129878
Systemic lupus erythematosus	76.31	10.17	44	77746	125370	53145906
Gallbladder injury	76.02	10.17	38	77752	1329	53269947
Emotional distress	75.56	10.17	154	77636	32163	53239113
Migraine	75.12	10.17	273	77517	80144	53191132
Therapeutic product effect decreased	72.40	10.17	47	77743	125608	53145668
Pericarditis	68.79	10.17	7	77783	64399	53206877
Infusion related reaction	66.09	10.17	78	77712	155879	53115397
Abdominal discomfort	63.32	10.17	143	77647	220919	53050357
Hepatic enzyme increased	61.50	10.17	56	77734	126139	53145137
Wound	58.78	10.17	30	77760	91527	53179749
Arthralgia	56.73	10.17	392	77398	439391	52831885
Accidental overdose	55.82	10.17	107	77683	21372	53249904
Rash	55.46	10.17	402	77388	445789	52825487
Serotonin syndrome	53.82	10.17	119	77671	26287	53244989
Snoring	52.80	10.17	44	77746	3748	53267528
Cholelithiasis	51.64	10.17	154	77636	40810	53230466
Alopecia	51.31	10.17	173	77617	234410	53036866
Muscle twitching	50.49	10.17	88	77702	16338	53254938
Product use issue	49.87	10.17	79	77711	139505	53131771
Therapeutic product effect incomplete	49.32	10.17	37	77753	91747	53179529
Respiratory arrest	49.01	10.17	133	77657	33407	53237869
Incoherent	48.68	10.17	46	77744	4626	53266650
Accidental death	46.27	10.17	30	77760	1734	53269542
Opisthotonus	46.20	10.17	18	77772	341	53270935
Dependence	45.60	10.17	32	77758	2109	53269167
Formication	44.61	10.17	41	77749	3980	53267296
Pulmonary haemorrhage neonatal	42.83	10.17	10	77780	25	53271251
Nasopharyngitis	42.59	10.17	141	77649	192154	53079122
Swelling	42.41	10.17	140	77650	190965	53080311
Mental status changes	40.95	10.17	139	77651	39432	53231844
Lethargy	40.82	10.17	171	77619	53589	53217687
Lower respiratory tract infection	40.15	10.17	44	77746	90937	53180339
Loss of consciousness	39.17	10.17	293	77497	113919	53157357
Hereditary angioedema	37.57	10.17	46	77744	6207	53265069
Pupillary reflex impaired	37.05	10.17	28	77762	2071	53269205
Suicidal ideation	36.62	10.17	180	77610	60331	53210945
Infection	36.28	10.17	129	77661	172076	53099200
Cardiac failure	36.27	10.17	43	77747	85801	53185475
Abdominal pain	35.95	10.17	548	77242	255355	53015921
Exposure via ingestion	35.74	10.17	33	77757	3222	53268054
Helicobacter infection	35.31	10.17	7	77783	39062	53232214
Dysarthria	33.95	10.17	133	77657	40435	53230841
Maternal exposure during pregnancy	33.85	10.17	115	77675	155524	53115752
Hypersensitivity	32.71	10.17	177	77613	210488	53060788
Deep vein thrombosis	32.67	10.17	220	77570	82693	53188583
Muscle injury	32.40	10.17	3	77787	29763	53241513
Drug hypersensitivity	32.39	10.17	555	77235	264687	53006589
Discomfort	32.26	10.17	56	77734	95416	53175860
Peripheral swelling	32.10	10.17	173	77617	205935	53065341
Impaired healing	31.85	10.17	28	77762	64177	53207099
Electrocardiogram QRS complex shortened	31.79	10.17	15	77775	461	53270815
Congenital tricuspid valve incompetence	31.76	10.17	10	77780	97	53271179
Depression	30.49	10.17	404	77386	182648	53088628
Folliculitis	30.13	10.17	5	77785	31704	53239572
C-reactive protein increased	29.77	10.17	33	77757	67853	53203423
Drug reaction with eosinophilia and systemic symptoms	29.38	10.17	6	77784	32794	53238482
General physical health deterioration	29.03	10.17	113	77677	146829	53124447
Newborn persistent pulmonary hypertension	28.51	10.17	10	77780	139	53271137
Neonatal hypotension	28.38	10.17	10	77780	141	53271135
Electrocardiogram QT prolonged	28.10	10.17	159	77631	56244	53215032
Anticholinergic syndrome	27.78	10.17	23	77767	1941	53269335
Drug screen positive	27.45	10.17	31	77759	3841	53267435
Drug abuser	27.19	10.17	28	77762	3125	53268151
Overdose	27.16	10.17	258	77532	107478	53163798
Dehydration	26.53	10.17	368	77422	168042	53103234
Cardiac arrest	25.99	10.17	229	77561	93438	53177838
Neonatal respiratory failure	24.81	10.17	10	77780	208	53271068
Restlessness	24.25	10.17	93	77697	27994	53243282
Product counterfeit	24.22	10.17	9	77781	149	53271127
Cholestasis	24.20	10.17	6	77784	28689	53242587
Impaired gastric emptying	23.43	10.17	45	77745	8998	53262278
Renal impairment	22.93	10.17	55	77735	83263	53188013
Somatic delusion	22.72	10.17	13	77777	599	53270677
Cardio-respiratory arrest	22.60	10.17	155	77635	58603	53212673
Mobility decreased	22.08	10.17	49	77741	76222	53195054
Neutropenia	21.90	10.17	139	77651	159046	53112230
Cholecystitis	21.81	10.17	60	77730	15186	53256090
Hyperreflexia	21.80	10.17	33	77757	5447	53265829
Gallbladder hypofunction	21.35	10.17	12	77778	534	53270742
Gastrointestinal disorder	21.31	10.17	64	77726	89940	53181336
Mental disorder	21.28	10.17	81	77709	24295	53246981
Hypopnoea	21.25	10.17	22	77768	2471	53268805
Arthritis	20.01	10.17	63	77727	87235	53184041
Gallbladder cholesterolosis	19.87	10.17	13	77777	763	53270513
Poor feeding infant	19.66	10.17	9	77781	258	53271018
Fatigue	18.99	10.17	1271	76519	729235	52542041
Drug withdrawal syndrome	18.87	10.17	86	77704	27936	53243340
Device expulsion	18.78	10.17	10	77780	29803	53241473
Cholecystectomy	18.62	10.17	43	77747	9772	53261504
Acute kidney injury	18.40	10.17	260	77530	253608	53017668
Pancreatitis chronic	18.16	10.17	20	77770	2410	53268866
Hip arthroplasty	18.07	10.17	9	77781	27853	53243423
Melaena	18.02	10.17	10	77780	29119	53242157
Cholesterosis	17.96	10.17	10	77780	437	53270839
Condition aggravated	17.94	10.17	315	77475	296819	52974457
Therapeutic response decreased	17.86	10.17	26	77764	47543	53223733
Pupil fixed	17.86	10.17	17	77773	1725	53269551
Seizure	17.63	10.17	276	77514	129233	53142043
Illness anxiety disorder	17.57	10.17	7	77783	141	53271135
Hepatocellular injury	17.55	10.17	11	77779	29975	53241301
Blood potassium decreased	17.54	10.17	110	77680	40350	53230926
Atrial septal defect	17.42	10.17	34	77756	6880	53264396
Coma blister	17.26	10.17	7	77783	148	53271128
Drug resistance	17.17	10.17	4	77786	19958	53251318
Helplessness	17.04	10.17	8	77782	243	53271033
Blood pressure fluctuation	16.96	10.17	16	77774	35454	53235822
Fall	16.87	10.17	396	77394	358044	52913232
Red blood cell sedimentation rate increased	16.83	10.17	10	77780	28047	53243229
Cytomegalovirus infection	16.64	10.17	4	77786	19535	53251741
Biliary colic	16.51	10.17	23	77767	3522	53267754
Miosis	15.93	10.17	33	77757	6969	53264307
Hyponatraemia	15.89	10.17	93	77697	108514	53162762
Musculoskeletal stiffness	15.82	10.17	110	77680	123258	53148018
Uterine perforation	15.76	10.17	34	77756	7385	53263891
Differential white blood cell count abnormal	15.62	10.17	11	77779	729	53270547
Blastocystis infection	15.52	10.17	4	77786	17	53271259
Product use in unapproved indication	15.46	10.17	98	77692	112191	53159085
Paranoia	15.40	10.17	44	77746	11380	53259896
Cough	15.29	10.17	273	77517	256620	53014656
Dyspnoea	14.90	10.17	701	77089	585531	52685745
Inflammation	14.72	10.17	39	77751	57097	53214179
Pneumocystis jirovecii pneumonia	14.66	10.17	3	77787	16375	53254901
Basal cell carcinoma	14.60	10.17	8	77782	23461	53247815
Pulmonary embolism	14.49	10.17	241	77549	114201	53157075
Ureteric stenosis	14.48	10.17	10	77780	642	53270634
Osteoporosis	14.15	10.17	29	77761	46431	53224845
Ill-defined disorder	14.11	10.17	32	77758	49412	53221864
pH body fluid increased	14.06	10.17	3	77787	4	53271272
Hypoglycaemia	13.94	10.17	42	77748	58971	53212305
Jaw clicking	13.85	10.17	4	77786	28	53271248
Sports injury	13.61	10.17	4	77786	30	53271246
Fear	13.47	10.17	54	77736	16587	53254689
Attention-seeking behaviour	13.39	10.17	5	77785	84	53271192
Herpes zoster	13.31	10.17	59	77731	73960	53197316
Intentional product misuse	13.30	10.17	120	77670	49272	53222004
Anhedonia	13.30	10.17	40	77750	10647	53260629
Fallot's tetralogy	13.02	10.17	5	77785	91	53271185
Ventricular septal defect	12.97	10.17	23	77767	4327	53266949
Loss of personal independence in daily activities	12.95	10.17	55	77735	69760	53201516
Interstitial lung disease	12.95	10.17	43	77747	58579	53212697
Unresponsive to stimuli	12.74	10.17	88	77702	33338	53237938
Heart rate increased	12.59	10.17	179	77611	82136	53189140
Base excess increased	12.51	10.17	4	77786	41	53271235
Vasoplegia syndrome	12.42	10.17	12	77778	1240	53270036
Osteonecrosis of jaw	12.39	10.17	21	77769	36125	53235151
Drug dependence	12.37	10.17	63	77727	21409	53249867
Stomatitis	12.34	10.17	88	77702	98070	53173206
Aggression	12.34	10.17	67	77723	23336	53247940
Hepatitis	12.27	10.17	19	77771	33875	53237401
Water intoxication	12.19	10.17	8	77782	472	53270804
Thrombocytopenia	11.92	10.17	137	77653	138590	53132686
Breast cancer	11.75	10.17	35	77755	49323	53221953
Chronic kidney disease	11.49	10.17	105	77685	43265	53228011
Pulmonary fibrosis	11.40	10.17	11	77779	24124	53247152
Fear of disease	11.39	10.17	11	77779	1136	53270140
Ischaemic stroke	11.39	10.17	6	77784	17987	53253289
Neuroleptic malignant syndrome	11.35	10.17	41	77749	11992	53259284
Infusion site macule	11.24	10.17	3	77787	15	53271261
Intestinal ischaemia	11.21	10.17	30	77760	7472	53263804
Finger amputation	11.20	10.17	8	77782	542	53270734
Small intestinal obstruction	11.09	10.17	52	77738	17095	53254181
Prolonged rupture of membranes	10.95	10.17	4	77786	63	53271213
Thinking abnormal	10.95	10.17	37	77753	10471	53260805
Jugular vein thrombosis	10.94	10.17	17	77773	2869	53268407
Acute lung injury	10.88	10.17	12	77778	1449	53269827
Injection site erythema	10.85	10.17	67	77723	77182	53194094
Hypophagia	10.81	10.17	80	77710	30982	53240294
Neonatal tachycardia	10.65	10.17	3	77787	19	53271257
Hyperkinetic heart syndrome	10.65	10.17	3	77787	19	53271257
Skin ulcer	10.62	10.17	23	77767	36096	53235180
Intestinal obstruction	10.57	10.17	75	77715	28666	53242610
Retroplacental haematoma	10.56	10.17	5	77785	155	53271121
Arm amputation	10.52	10.17	3	77787	20	53271256
Heart rate decreased	10.47	10.17	24	77766	36923	53234353
Lentigo	10.46	10.17	6	77784	278	53270998
Retching	10.32	10.17	44	77746	13889	53257387
Bradycardia	10.31	10.17	61	77729	70995	53200281
Tremor	10.28	10.17	248	77542	125488	53145788
Disorientation	10.28	10.17	95	77695	39264	53232012
Respiratory rate decreased	10.23	10.17	18	77772	3366	53267910
Femur fracture	10.21	10.17	27	77763	39558	53231718
Therapy non-responder	10.19	10.17	37	77753	49083	53222193
Knee arthroplasty	10.18	10.17	21	77769	33548	53237728

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Intentional self-injury	1967.93	11.16	666	30101	13234	32469525
Intentional overdose	1549.74	11.16	764	30003	40837	32441922
Akathisia	146.07	11.16	88	30679	6937	32475822
Depressed level of consciousness	104.76	11.16	159	30608	40688	32442071
Neuroleptic malignant syndrome	87.64	11.16	95	30672	17400	32465359
Tachycardia	83.89	11.16	212	30555	78876	32403883
Agitation	68.75	11.16	161	30606	57075	32425684
Respiratory arrest	66.40	11.16	107	30660	28801	32453958
Nausea	64.18	11.16	520	30247	320329	32162430
Vomiting	63.96	11.16	411	30356	235146	32247613
Sinus tachycardia	63.47	11.16	78	30689	16336	32466423
Somnolence	61.66	11.16	227	30540	103570	32379189
Drug ineffective	60.10	11.16	176	30591	383301	32099458
Off label use	59.33	11.16	126	30641	306194	32176565
Mydriasis	59.23	11.16	49	30718	6397	32476362
Toxicity to various agents	54.14	11.16	320	30447	177721	32305038
Poisoning	49.70	11.16	57	30710	11101	32471658
Product counterfeit	41.99	11.16	13	30754	190	32482569
Drug abuse	40.69	11.16	167	30600	80076	32402683
Overdose	39.35	11.16	175	30592	86902	32395857
Lethargy	38.04	11.16	105	30662	41123	32441636
Exposure during pregnancy	37.53	11.16	45	30722	9184	32473575
Dysarthria	35.15	11.16	89	30678	33112	32449647
Hallucination	31.97	11.16	116	30651	52503	32430256
Dystonia	31.03	11.16	44	30723	10579	32472180
Loss of consciousness	30.66	11.16	157	30610	82550	32400209
Cardio-respiratory arrest	30.35	11.16	119	30648	55870	32426889
Consciousness fluctuating	29.04	11.16	16	30751	1064	32481695
Anxiety	26.23	11.16	168	30599	95837	32386922
Dehydration	25.61	11.16	209	30558	128749	32354010
Interstitial lung disease	25.38	11.16	15	30752	64986	32417773
Dextrocardia	25.23	11.16	8	30759	127	32482632
General physical health deterioration	25.19	11.16	44	30723	115215	32367544
Completed suicide	24.72	11.16	161	30606	92356	32390403
Serotonin syndrome	24.27	11.16	55	30712	19062	32463697
Pyomyositis	24.09	11.16	8	30759	148	32482611
Foetal alcohol syndrome	24.09	11.16	8	30759	148	32482611
Acute kidney injury	23.49	11.16	172	30595	293296	32189463
Renal impairment	22.08	11.16	33	30734	91939	32390820
Atrial septal defect	21.87	11.16	30	30737	6995	32475764
Failure to thrive	21.83	11.16	33	30734	8402	32474357
Exposure via ingestion	21.82	11.16	18	30749	2339	32480420
Opisthotonus	21.72	11.16	10	30757	453	32482306
Suicide attempt	21.30	11.16	82	30685	38162	32444597
Sedation	21.01	11.16	51	30716	18475	32464284
General symptom	20.70	11.16	12	30755	880	32481879
Paralysis	20.22	11.16	27	30740	6136	32476623
Foetal exposure during pregnancy	20.16	11.16	85	30682	41216	32441543
Hepatic ischaemia	19.73	11.16	9	30758	399	32482360
Breathing-related sleep disorder	18.92	11.16	7	30760	180	32482579
Confusional state	18.53	11.16	212	30555	142903	32339856
Drug withdrawal syndrome neonatal	17.22	11.16	19	30748	3545	32479214
Therapeutic product effect incomplete	16.91	11.16	9	30758	41332	32441427
Pupil fixed	16.85	11.16	14	30753	1837	32480922
Respiratory depression	16.76	11.16	38	30729	13173	32469586
Rheumatoid arthritis	16.39	11.16	11	30756	44533	32438226
Angioedema	16.22	11.16	7	30760	36282	32446477
Drug withdrawal syndrome	16.21	11.16	49	30718	20182	32462577
Psychomotor hyperactivity	16.21	11.16	30	30737	9009	32473750
Conduction disorder	15.97	11.16	14	30753	1976	32480783
Obsessive thoughts	15.25	11.16	9	30758	682	32482077
Red blood cells urine positive	15.22	11.16	13	30754	1773	32480986
Cardiac arrest	15.16	11.16	149	30618	96627	32386132
Patent ductus arteriosus	15.00	11.16	17	30750	3268	32479491
Fallot's tetralogy	14.90	11.16	6	30761	195	32482564
Inappropriate schedule of product administration	14.72	11.16	13	30754	45812	32436947
Condition aggravated	14.55	11.16	87	30680	155574	32327185
Unresponsive to stimuli	14.40	11.16	58	30709	27551	32455208
Skin swelling	14.14	11.16	10	30757	1034	32481725
Snoring	14.11	11.16	16	30751	3077	32479682
Drug hypersensitivity	14.03	11.16	118	30649	73282	32409477
Fatigue	13.95	11.16	432	30335	350269	32132490
Upper respiratory tract irritation	13.88	11.16	4	30763	45	32482714
Incision site pain	13.74	11.16	13	30754	2024	32480735
Psoriasis	13.74	11.16	14	30753	46109	32436650
Linear IgA disease	13.68	11.16	12	30755	1696	32481063
Product use in unapproved indication	13.58	11.16	40	30727	87164	32395595
Cardiomegaly	13.51	11.16	38	30729	15033	32467726
Environmental exposure	13.35	11.16	6	30761	257	32482502
Protein urine present	13.27	11.16	20	30747	5077	32477682
Poor quality product administered	13.24	11.16	12	30755	1769	32480990
Foetal death	13.24	11.16	6	30761	262	32482497
Hyperkalaemia	13.18	11.16	29	30738	69721	32413038
Myocardial infarction	12.96	11.16	68	30699	125608	32357151
Accidental overdose	12.91	11.16	44	30723	19295	32463464
Hepatocellular injury	12.80	11.16	4	30763	25314	32457445
Drug resistance	12.80	11.16	3	30764	22962	32459797
Restlessness	12.76	11.16	52	30715	24829	32457930
Treatment failure	12.71	11.16	11	30756	39152	32443607
Psychotic disorder	12.52	11.16	49	30718	22971	32459788
Cholestasis	12.43	11.16	5	30762	27028	32455731
Acute chest syndrome	12.28	11.16	6	30761	311	32482448
Drug interaction	12.15	11.16	140	30627	218045	32264714
Tardive dyskinesia	12.05	11.16	20	30747	5511	32477248
Aggression	12.05	11.16	71	30696	39318	32443441
Small for dates baby	11.34	11.16	15	30752	3378	32479381

Pharmacologic Action:

Source	Code	Description
ATC	D04AA10	DERMATOLOGICALS ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. Antihistamines for topical use
ATC	R06AD02	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Phenothiazine derivatives
ATC	R06AD52	RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Phenothiazine derivatives
ATC	V03AB05	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes
FDA CS	M0016525	Phenothiazines
MeSH PA	D018926	Anti-Allergic Agents
MeSH PA	D000982	Antipruritics
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006634	Histamine H1 Antagonists
MeSH PA	D018377	Neurotransmitter Agents
CHEBI has role	CHEBI:35717	sedatives
CHEBI has role	CHEBI:36333	local anaesthetics
CHEBI has role	CHEBI:37955	H1-receptor blockers
CHEBI has role	CHEBI:50857	anti-allergic agents
CHEBI has role	CHEBI:50919	antiemetico
CHEBI has role	CHEBI:59683	anti-itching drug
CHEBI has role	CHEBI:149553	anti-coronaviral agents
CHEBI has role	CHEBI:176497	anti-aging drugs
FDA EPC	N0000175746	Phenothiazine

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Vasomotor rhinitis	indication	8229003	DOID:4730
Nausea and vomiting	indication	16932000
General anesthesia	indication	50697003
Sedation	indication	72641008
Urticaria	indication	126485001
Seasonal allergic rhinitis	indication	367498001
Allergic conjunctivitis	indication	473460002	DOID:11204

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.19	Basic
pKa2	3.55	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	9.62	WOMBAT-PK	CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		Ki	6.61	WOMBAT-PK
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.59	DRUG MATRIX
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.92	DRUG MATRIX
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		IC50	5.12	CHEMBL
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.38	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.83	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	6.77	WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.37	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	8.19	DRUG MATRIX
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	5.95	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN				WOMBAT-PK
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	7.62	DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.72	DRUG MATRIX
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	5.94	DRUG MATRIX
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		Ki	6.82	WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	8.48	DRUG MATRIX
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.92	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	8.38	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	8.98	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	8.48	DRUG MATRIX
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	6.29	WOMBAT-PK
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.45	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		Ki	5.42	WOMBAT-PK
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN		Ki	7.50	DRUG MATRIX
Cholinesterase	Enzyme	P06276	CHLE_HUMAN		Ki	7.10	WOMBAT-PK
Major prion protein	Surface antigen	P04156	PRIO_HUMAN		EC50	5.10	CHEMBL
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.45	CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	5.16	CHEMBL
FAD-linked sulfhydryl oxidase ALR	Enzyme	P55789	ALR_HUMAN		AC50	6.44	CHEMBL
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	5.86	DRUG MATRIX
Calmodulin-1	Cytosolic other	P0DP23	CALM1_HUMAN		IC50	4.22	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	7.68	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	7.10	CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		IC50	5.59	CHEMBL
Pleiotropic ABC efflux transporter of multiple drugs	Transporter		PDR5_YEAST		IC50	4.75	CHEMBL
Chloroquine resistance transporter	Transporter		CRT_PLAFA		IC50	4.07	CHEMBL
Calmodulin	Cytosolic other		CALM_BOVIN		Kd	4.30	CHEMBL

External reference:

ID	Source
4019910	VUID
N0000147995	NUI
D00480	KEGG_DRUG
58-33-3	SECONDARY_CAS_RN
4017846	VANDF
4019910	VANDF
C0033405	UMLSCUI
CHEBI:8461	CHEBI
CHEMBL1200750	ChEMBL_ID
CHEMBL251904	ChEMBL_ID
CHEMBL643	ChEMBL_ID
DB01069	DRUGBANK_ID
D011398	MESH_DESCRIPTOR_UI
4927	PUBCHEM_CID
7282	IUPHAR_LIGAND_ID
516	INN_ID
FF28EJQ494	UNII
142445	RXNORM
2141	MMSL
5367	MMSL
d00787	MMSL
001483	NDDF
004459	NDDF
14905007	SNOMEDCT_US
372871004	SNOMEDCT_US
8372007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0547	SYRUP	6.25 mg	ORAL	ANDA	30 sections
Promethazine VC with Codeine Oral Solution	HUMAN PRESCRIPTION DRUG LABEL	3	0121-0925	SOLUTION	6.25 mg	ORAL	ANDA	29 sections
Promethazine VC	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0926	SOLUTION	6.25 mg	ORAL	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0927	SOLUTION	6.25 mg	ORAL	ANDA	25 sections
Promethazine with Codeine	HUMAN PRESCRIPTION DRUG LABEL	2	0121-0928	SOLUTION	6.25 mg	ORAL	ANDA	29 sections
PROMETHAZINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9940	INJECTION	25 mg	INTRAMUSCULAR	ANDA	12 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9941	INJECTION	25 mg	INTRAMUSCULAR	ANDA	12 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9942	INJECTION	50 mg	INTRAMUSCULAR	ANDA	12 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-5195	TABLET	25 mg	ORAL	ANDA	11 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0440-8195	TABLET	25 mg	ORAL	ANDA	12 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-5307	TABLET	25 mg	ORAL	ANDA	24 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-5319	TABLET	50 mg	ORAL	ANDA	24 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8154	TABLET	25 mg	ORAL	ANDA	21 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0928	INJECTION	25 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0929	INJECTION	50 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0948	INJECTION	25 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0949	INJECTION	50 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0955	INJECTION	25 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-0956	INJECTION	50 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-1495	INJECTION	25 mg	INTRAMUSCULAR	ANDA	25 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-1496	INJECTION	50 mg	INTRAMUSCULAR	ANDA	25 sections
PHENERGAN	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6082	INJECTION	25 mg	INTRAMUSCULAR	ANDA	25 sections
PHENERGAN	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6083	INJECTION	50 mg	INTRAMUSCULAR	ANDA	25 sections
PHENERGAN	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6084	INJECTION	25 mg	INTRAMUSCULAR	ANDA	26 sections
PHENERGAN	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6085	INJECTION	50 mg	INTRAMUSCULAR	ANDA	26 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6099	INJECTION	25 mg	INTRAMUSCULAR	ANDA	26 sections
Promethazine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6208	INJECTION	25 mg	INTRAMUSCULAR	ANDA	25 sections
PROMETHEGAN	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0132	SUPPOSITORY	50 mg	RECTAL	ANDA	21 sections
PROMETHEGAN	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0526	SUPPOSITORY	25 mg	RECTAL	ANDA	21 sections
PROMETHEGAN	HUMAN PRESCRIPTION DRUG LABEL	1	0713-0536	SUPPOSITORY	12.50 mg	RECTAL	ANDA	21 sections